Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity

Molecular Cancer Therapeutics

Volumn 8, Issue 7, 2009, Pages 1828-1837

  Thomas, Huw D ^a   Saravanan, Kappusamy ^b   Wang, Lan Zhen ^a   Lin, Mei Ju ^a   Northen, Julian S ^b   Barlow, Hannah ^b   Barton, Marion ^b   Newell, David R ^a   Griffin, Roger J ^b   Golding, Bernard T ^b   Curtin, Nicola J ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DIPYRIDAMOLE; DNA; FOLIC ACID ANTAGONIST; HYPOXANTHINE; NU 3108; NU 3144; NU 3150; NU 3151; NU 3153; NU 3166; NUCLEIC ACID BASE; NUCLEOSIDE; NUCLEOSIDE TRANSPORT INHIBITOR; OROSOMUCOID; PEMETREXED; PLASMA PROTEIN; PRODRUG; PYRIMIDINE DERIVATIVE; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL PROLIFERATION; DIPYRIDAMOLE; DRUG SYNERGISM; FEMALE; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; LEUKEMIA L1210; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEOSIDES; OROSOMUCOID; PHOSPHORYLATION; PRODRUGS; THYMIDINE; THYMIDYLATE SYNTHASE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651160505     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1208     Document Type: Article

References (27)

1. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamics and clinical properties of antifolates. Invest New Drugs 2006;24:37-77.
2. Weber G. Biochemical strategy of cancer cells an the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res 1983;43:3466-92.
3. Kinsella AR, Harran MS. Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts. Cancer Res 1991;51:1855-9.
4. Webber S, Bartlett CA, Boritzki TJ, et al. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and preclinical studies. Cancer Chemother Pharmacol 1996;37:509-17.
5. Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate LY231514. Anticancer Res 1998;18:3235-40.
6. Schultz RM, Patel VF,Worzalla JF, Shih C. Role of thymidylate synthase in the antitumour activity of the multitargeted antifolate LY231514. Anticancer Res 1999;19:437-44.
7. Baldwin SA, Mackey JR, Cass CE, Young JD. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 1999;5:216-24.
8. Schaper W. Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs Ther 2005;19:357-63.
9. Goel R, Howell SB. Modulation of the activity of cancer chemotherapeutic agents by dipyridamole. In: Muggia FM, editor. New drugs, concepts and results in cancer chemotherapy. Boston: Kluwer Academic Publishers 1992; 19-44.
10. Curtin NJ, Harris AL, Aherne GW. Mechanismof cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 1991;51:2346-52.
11. Curtin NJ, Newell DR, Harris AL. Modulation of dipyridamole action by α1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole. Biochem Pharmacol 1989;38:3281-8.
12. Willson JKV, Fischer PH, Remick SC, et al. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. Cancer Res 1988;48:5585-90.
13. Budd GT, Jayaraj A, Grabowski D, et al. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid. Cancer Res 1990;50:7206-11.
14. 1-acid glycoprotein binding. Br J Cancer 1999;80:1738-46.
15. 1-acid glycoprotein. Journal of Medicinal Chemistry 2004;47:4905-22.
16. Smith PG, Thomas HD, Barlow HC, et al. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. Clin Cancer Res 2001;7:2105-13.
17. Smith PJ, Marshman E, Newell DR, Curtin NJ. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. Br J Cancer 2000;82:924-30.
18. Curtin NJ, Harris AL. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in A549 cells. Biochem Pharmacol 1998;37:2113-20.
19. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:110-2.
20. Marshman E, Taylor GA, Thomas HD, Newell DR, Curtin NJ. Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole. Biochem Pharmacol 2001;61:477-84.
21. Wohlhueter RM, Marz R, Graff JC, Plagemann PGW. A rapid-mixing technique to measure transport in suspended animal cells: applications to nucleoside transport in Novikoff rat hepatoma cells. Methods Cell Biol 1978;20:211-36.
22. Asoh K-I, Yoshio S, Sato S-I, Nogae I, Kohno K, Kuwano M. Potentiation of some anticancer agents by dipyridamole against drug-sensitive and drug-resistant cancer cell lines. Jpn J Cancer Res 1990;80:475-81.
23. Curtin NJ, Turner DP. Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro. Eur J Cancer 1999;35:1020-6.
24. Polgar O, Robey RW, Bates SE. ABCG2: structure, function and role in drug response. Expert Opin Drug Metabol Toxicol 2008;4:1-5.
25. WormJ, Kirkin AF, Dzhandzhugazyan KN, Guldberg P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate- resistant human breast cancer cells. J Biol Chem 2001;276:39990-40000.
26. Jackman AL, Taylor GA, Calvert AH, Harrap KR. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazolinebased thymidylate synthetase inhibitor, CB3717. Biochem Pharmacol 1984;33:3269-75.
27. Li KM, Rivory LP, Hoskins J, Sharma R, Clarke SJ. Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. Br J Clin Pharmacol 2006;63:67-74.